- Malaysia senior secured syndicated term financing upsized to approximately US$7.2 billion in total for Johor platform

- 1GW of IT Power Capacity now generating income under long-term customer contracts; 2.3GW of Bookings[1,2]committed by customers and Reservations[3] of 1.1GW

- Showcasing DayOne's ability to deliver on customer commitments at scale

SINGAPORE, Oct. 14, 2026 /PRNewswire/ -- DayOne Data Centers Limited ("DayOne"), a Singapore-headquartered global digital infrastructure platform, today announced it has surpassed 1GW of Billings[4]. This follows the recent upsize of its senior secured multi-currency syndicated term financing in Malaysia to approximately US$7.2 billion in total. These milestones demonstrate DayOne's ability to deliver on customer commitments and execute at scale.

DayOne continues to strengthen its capital base to support its growth. Arranged by a seven-lender consortium, the upsized financing of approximately US$7.2 billion in Malaysia supports the continued development of its data center platform in Johor and builds on the approximately US$3.5 billion syndicated financing the company secured in May 2025. Since 2024, the company has raised over US$6 billion in equity across several financing rounds, alongside project financing from a broad roster of more than 30 local and global banking partners.

DayOne's Billings have grown over eightfold in under two years, from 121MW at the end of 2024. The 1GW Billings milestone comes as DayOne's Bookings reached approximately 2.3GW[1], up from 1.25GW at the end of 2025. In addition to the Bookings, DayOne also had 1.1GW[1] of Reservations[3] from customers.

Jamie Khoo, Chief Executive Officer of DayOne, said, "The confidence our banking partners and customers have placed in DayOne is reflected in these milestones and underpins our continued growth. Together, their support has enabled us to unlock strategic capacity for the next generation of AI and cloud infrastructure. Our focus remains on earning that trust through responsible execution and bringing capacity online at speed and scale in the markets our customers need."

DayOne acquires powered land and secures anchor customer commitments early on in its development process. Across its ten-market footprint, DayOne's Resources[5] reached 4.6GW[1], up from 2GW at the end of 2025.

A key part of DayOne's growth strategy is to continue broadening and diversifying its customer base over time. Bookings came from 15 customers[1], up from nine at the end of 2024. Four of its top five customers are with DayOne in multiple markets. Three hyperscale customers each have multi-market deployments of around or above 200MW. Most recently, DayOne has secured additional orders with one of its existing U.S. hyperscale customers.

"By pioneering and scaling new markets, this conviction has shaped DayOne since inception, and it continues to guide how we grow," added Jamie. "From Singapore where DayOne was founded, we are driving the delivery of high-specification facilities across Asia Pacific and Europe."

About DayOne Data Centers

DayOne Data Centers Limited ("DayOne") is a Singapore-headquartered global digital infrastructure platform that develops and operates next-generation data centers, with a footprint across ten markets in Asia Pacific and Europe. Trusted by leading global hyperscalers and businesses, DayOne engineers, builds, and operates high-capacity, AI-ready campuses with speed, scale, and reliability. Powered by its proprietary integrated delivery model and proven track record of pioneering and scaling new markets, DayOne unlocks strategic capacity to meet accelerating critical infrastructure demands. Established in 2022, DayOne has operations in Singapore, Johor and Greater Kuala Lumpur in Malaysia, Indonesia, Thailand, Tokyo and Kyushu in Japan, Hong Kong SAR, Finland, and Spain. For more information, visit dayonedc.com.

SOURCE DayOne Data Centers Limited

Share this article

Luxury Prices Fall for 30th Straight Month as Big Price Tags Fail to Guarantee Top School Marks, Realtor.com® Finds

Naples, Fla., tops luxury markets in elementary school ratings (9.3/10) and annual price gains, while second-priciest Kahului-Wailuku, Hawaii, ranks last (5.0/10)

AUSTIN, Texas, Oct. 14, 2026 /PRNewswire/ -- The national entry point to luxury housing edged down to $1,199,321 in September, 3.6% below a year ago and the 30th consecutive month of annual price declines, according to the Realtor.com® September Luxury Housing Report released today.

Every luxury tier is cheaper than a year ago, with the threshold for the top 5% of listings down 3.5% and the top 1% down 5.3%. Even so, luxury homes are selling faster than they were last September. Listings at the 90th percentile spent a median of 76 days on the market, three days fewer than a year ago, though two days more than in August as the market eases out of summer.

With students back in class, the report also looks at public elementary school ratings across luxury markets and finds that a big price tag doesn't guarantee top marks.

"Luxury prices keep drifting lower, but buyers haven't gone quiet. Homes are selling faster than a year ago in every tier," said Anthony Smith, senior economist at Realtor.com®. "School ratings are one local factor that can go hand in hand with price strength, as in Naples, Fla., but they don't make a market immune."

National Luxury Overview, September 2026

The luxury entry point is the lowest since January 2023, 14.1% below its May 2023 peak of roughly $1.4 million. It slipped 0.1% from August, following a 4.0% drop that month, and higher tiers softened slightly more. There are no clear signs yet of a reversal.

The million-dollar listing share fell to 12.5%, down 0.2 percentage points from August and 0.5 points from a year ago. Million-dollar listings rose 1.2% from last year while total active listings rose 5.4%. Listings at the 95th percentile spent 86 days on the market and those at the 99th percentile spent 100 days, each three days faster than a year ago. The typical listing spent 61 days on the market, unchanged from a year ago.

Los Angeles Widens Its Lead as the Highest Entry Point to Luxury

Los Angeles held the top spot at $3.95 million in September, widening its lead as Kahului-Wailuku, Hawaii, slipped 3.1%. The gap between the top two is now about 4%, after less than 1% separated the top three in August. Naples-Marco Island, Fla., moved up to third.

Bridgeport-Stamford-Danbury, Conn., fell 7.3% after a 6.0% drop in August. It is now 15.6% below a year ago, the steepest annual decline in the top 10, and 14.3% below its June peak, when it held the top spot.

Naples, Fla., (up 8.9%) and Crestview-Fort Walton Beach-Destin, Fla,. (up 2.4%) were the only top 10 markets with annual gains. San Jose-Sunnyvale-Santa Clara, Calif., posted a third straight monthly gain but remains 10.8% below a year ago. San Francisco-Oakland-Fremont, Calif., returned to the top 10, pushing out Atlantic City-Hammonton, N.J.

Top 10 Most Expensive Metropolitan Luxury Markets

Back to School: Luxury Markets and Elementary School Ratings

Location drives luxury purchases, and for many buyers that includes schools. The report compares average public elementary school ratings from GreatSchools.org for luxury homes (listings at or above the metro's 90th percentile) across the 43 metropolitan areas it tracks. Naples-Marco Island, Fla., ranks first at 9.3 out of 10, followed by Crestview-Fort Walton Beach-Destin, Fla., at 9.1 and Bridgeport. Conn., at 8.5. Naples and Crestview are also the only two top 10 most expensive markets with annual price gains.

Metros With the Highest-Rated Elementary Schools Among Luxury Markets

Strong elementary schools aren't a shield, however. Bridgeport, Conn., ranks third on elementary schools, but its luxury threshold is down 15.6% from a year ago. The price tag isn't a grade either. Luxury begins at $900,388 in Jacksonville, Fla., and $780,487 in San Antonio-New Braunfels, Texas, and both average higher elementary school ratings (7.8 and 7.4) than New York (6.7), where luxury starts at $2.62 million.

At the other end, Kahului-Wailuku, Hawaii, averages 5 out of 10, the lowest of any luxury metro and 4.3 points below Naples, Fla., despite having the second-highest luxury threshold. Urban Honolulu follows at 5.7.

Metros With the Lowest-Rated Elementary Schools Among Luxury Markets

The ratings cover public schools only, and many luxury buyers also weigh private options. School quality is one local factor among several and not a reliable predictor of price performance.

Methodology

All data in this report is sourced from Realtor.com® listing trends as of September 2026, reflecting active inventory of existing homes, including single-family residences, condos, townhomes, row homes and co-ops. Listings reflect only those provided by MLS platforms to Realtor.com® via a listing feed. New-construction listings are excluded unless actively listed on participating MLSs.

Luxury segmentation is based on market-specific price percentiles, with the 90th percentile representing entry-level luxury, the 95th percentile marking high-end luxury and the 99th percentile indicating ultraluxury. All calculations are based on listing prices, not final sales prices.

Metropolitan and micropolitan areas are defined using the Office of Management and Budget's OMB-2023 delineations, with Claritas 2025 household estimates used for relative comparisons. Where appropriate, analysis was limited to metros or micros with a minimum threshold of active million-dollar listings on average over the past year. Market-level analysis in this report covers the 43 metropolitan areas that averaged at least 500 million-dollar listings over the 12 months through September 2026.

School ratings are sourced from GreatSchools.org and reflect the 1 to 10 rating of the public elementary schools assigned to each listing. Homes without an assigned elementary school rating are excluded. Ratings do not reflect private schools, school choice programs or lottery-based admissions.

Historical listing trend data extends to July 2016, but year-over-year comparisons in this report use September 2025 as the baseline.

Luxury by the Numbers

90th percentile = Entry-level luxury (top 10% of prices)

95th percentile = High-end luxury

99th percentile = Ultraluxury (often rare or custom properties)

About Realtor.com®

For over 30 years, Realtor.com® has connected buyers, sellers, and renters with trusted insights, professional guidance and powerful tools to help them find their perfect home. Recognized as the No. 1 real estate site REALTOR® agents recommend, Realtor.com® delivers consumer connections and a robust suite of marketing tools to support business growth. Realtor.com® is operated by News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV] subsidiary Move, Inc.

Media contact: Janice McDill, [email protected]

SOURCE Realtor.com

Share this article

Huya Earns Back-to-Back Recognition from Renowned Media Brands Barron's China and Forbes China

GUANGZHOU, China, Oct. 14, 2026 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that it recently received back-to-back industry accolades from two eminent business media brands, Barron's China and Forbes China. These honors highlight Huya's progress in its strategic transformation and its expanding role across the game ecosystem.

Huya was named to the Value Industry Benchmark 30 on the 2026 Barron's China Value List in the Integrated Game Ecosystem Services segment. The selection recognizes Huya's strong performance across the list's four assessment dimensions: Financial Integrity, Capital Quality, Pricing Power and Barron's Proprietary Data.

Huya also received a national award in the frontier innovation segment of the 2025 Forbes China Novel Intelligent Economy Selection for its creative use of AI and technological innovation to advance its game ecosystem and enhance its integrated game-related services.

Since launching its strategic transformation in August 2023, Huya has steadily expanded its game-related services, including game distribution, in-game item sales and game publishing. Goose Goose Duck mobile's successful debut and strong performance have validated Huya's content-led game publishing model, and The Legend of Swordman: Reunion and Xiao Xiao Qi Yu are progressing toward launch.

Huya is also advancing AI applications in live streaming, game tools and IP-based companionship. In July 2026, the Company unveiled VAM 1.0, its self-developed real-time multimodal digital human model, which can rapidly generate AI-powered virtual hosts capable of natural speech, singing, and expressive body movements, enabling lifelike, real-time interactions. VAM 1.0 is also expected to improve content production efficiency.

In the second quarter of 2026, Huya's total net revenues increased 11.0% year over year to RMB1,739.3 million. Game-related services, advertising and other revenues rose 54.1% to RMB637.9 million, representing 36.7% of total net revenues. Huya also doubled the authorized repurchase amount under its 2026 Share Repurchase Program to US$100 million.

Looking ahead, Huya will continue to drive innovation and strengthen its position as a leading game-related entertainment and services provider. Supported by a solid financial foundation, the Company aims to draw on its content ecosystem, streamer network, user base, AI technologies and industry partnerships to capture new growth opportunities and create long-term value for shareholders, users and industry partners.

About HUYA Inc.

HUYA Inc. is a leading game-related entertainment and services provider. Huya delivers dynamic live streaming and video content and a rich array of services spanning games, e-sports, and other interactive entertainment genres to a large, highly engaged community of game enthusiasts. Huya has cultivated a robust entertainment ecosystem powered by AI and other advanced technologies, serving users and partners across the gaming universe, including game companies, e-sports tournament organizers, broadcasters and talent agencies. Leveraging this strong foundation, Huya has also expanded into innovative game-related services, such as game distribution, in-game item sales, advertising and more. Huya continues to extend its footprint in China and abroad, meeting the evolving needs of gamers, content creators, and industry partners worldwide.

For more information, please visit: https://ir.huya.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, Huya's strategic and operational plans in this announcement contain forward-looking statements. Huya may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Huya's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Huya's goals and strategies; Huya's future business development, results of operations and financial condition; the expected growth of the live streaming industry and the game industry in Chinese mainland and internationally; Huya's expectation regarding demand for and market acceptance of its products and services; Huya's ability to retain and grow its user reach, broadcasters, talent agencies, business partners for game-related services and advertisers; Huya's ability to expand its product and service offerings; competition in the live streaming industry and game industry; Huya's efforts in complying with applicable data privacy and security regulations; fluctuations in general economic and business conditions in China; the economy in China and elsewhere generally; any regulatory developments in laws, regulations, rules, policies or guidelines applicable to Huya; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Huya's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Huya does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

HUYA Inc.

Investor Relations

Tel: +86-20-2290-7829

E-mail: [email protected] 

Piacente Financial Communications

Jenny Cai

Tel: +86-10-6508-0677

E-mail: [email protected] 

In the United States:

Piacente Financial Communications

Brandi Piacente

Tel: +1-212-481-2050

E-mail: [email protected] 

SOURCE HUYA Inc.

Share this article

All amounts are expressed in United States dollars unless otherwise stated.

TORONTO, Oct. 14, 2026 /PRNewswire/ -- i-80 GOLD CORP. (NYSE: IAUX) (TSX: IAU) ("i-80 Gold", or the "Company") is pleased to provide an update on its Nevada development plan. Operating and near-term development projects continue to advance on schedule toward a total annual production target of 150,000 to 200,000 ounces of gold starting in 2028.(1) In addition, the Company's development plan has been updated to prioritize Mineral Point open pit as the Company's next major development project following the anticipated establishment of its underground hub-and-spoke mining and processing platform to create a Nevada-focused mid-tier gold producer.

Development Highlights

- Archimedes underground on track to commence production mining: Development at Archimedes, the Company's second underground mine, continues to advance on schedule toward the start of production mining in the fourth quarter of 2026, as planned.

- Lone Tree Plant refurbishment advances toward initial construction: Bulk demolition activities are complete, and mobilization is underway for initial construction activities to commence in the fourth quarter of 2026, as planned. Capital expenditures remain largely on budget with approximately 10% of the total project contingency drawn down to date.

- Exploration upside drives updated development plan: Mineral resource expansion potential at the Granite Creek and Archimedes underground projects support the Company's view that these deposits have the potential to supply sufficient feed to the Lone Tree Plant for longer than previously contemplated, providing flexibility to sequence Cove underground later in the development plan as a future source of refractory feed to the Lone Tree Plant when required.

- Mineral Point open pit prioritized ahead of Granite Creek open pit: Mineral Point is the Company's most valuable project. It hosts a large gold-silver oxide resource and the potential to add annual production of approximately 280,000 gold equivalent ounces over a mine life of 17 years, based on the related preliminary economic assessment ("PEA") filed in March 2025.(1) The updated development plan prioritizes the Mineral Point open pit oxide project to drive the next phase of production growth ahead of the Granite Creek open pit oxide project.

- Oxide mineralization identified within the Archimedes underground 426 zone provides significant low-cost processing opportunity: Ongoing metallurgical test work demonstrates the potential to process this oxide material, which was not included in the related March 2025 PEA, on the Ruby Hill property's existing active heap leach pad, providing a significantly lower cost processing option than assumed in the PEA mine plan.

"We are pleased with the continued progress across our operating and near-term development projects as we continue to achieve each major milestone on schedule," stated Richard Young, President & Chief Executive Officer. "Granite Creek underground is ramping up production, and its measured and indicated mineral resources increased by approximately 230% in the September 2026 feasibility study(2) compared with the March 2025 PEA. Thanks to the dedication of our project teams, Archimedes underground remains on track to begin production mining in the fourth quarter of 2026, while the Lone Tree Plant refurbishment continues to advance on schedule toward its first gold pour target in the fourth quarter of 2027."

Mr. Paul Chawrun, Executive Vice President and Chief Operating Officer added, "Ongoing drilling and technical work continue to reinforce our confidence in the resource expansion potential at Granite Creek and Archimedes underground, and their potential to supply refractory feed to the Lone Tree Plant for longer than previously contemplated. This creates an opportunity to sequence Cove underground later in the development pipeline as a future source of refractory feed and prioritize Mineral Point open pit, our largest growth project, to drive the next stage of production growth. We believe this updated development plan positions us to unlock Mineral Point's substantial value while aligning capital allocation with feed supply and processing capacity. It also continues to support organic growth toward a target of 500,000 to 600,000 ounces of average annual gold production under our broader development plan, and our goal of becoming a mid-tier gold producer in Nevada."(1)

Project Updates

Archimedes Underground

Archimedes underground continues to advance toward first gold mined in the fourth quarter of 2026. Drilling, resource modelling and metallurgical test work are underway to support the feasibility study targeted for completion in approximately mid-2027, pending the timing of additional drilling.(2)

Consistent with previously reported results, ongoing drilling continues to intersect significant intervals of oxide mineralization outside the mineral resource estimate supporting the March 2025 PEA, highlighting potential upside to the PEA mine plan through anticipated lower overall processing costs driven by the oxide portion of the resource. Building on recommendations in the PEA, the Company is evaluating the potential to process this oxide material on the existing active heap leach facilities on the Ruby Hill property where Archimedes is located. Preliminary work indicates an opportunity to heap leach more oxide material than contemplated in the PEA, potentially reducing processing costs relative to processing through the Lone Tree's carbon-in-leach ("CIL") circuit. Metallurgical test work remains ongoing to establish recoveries and assess the viability of this processing option. Refractory material is expected to be stockpiled ahead of Lone Tree's commissioning. Drilling in the lower 426 and Ruby Deeps zones is also evaluating extensions to the mineralized system and the potential to support a longer-term supply of refractory feed to Lone Tree.

Lone Tree Plant Refurbishment

Once refurbished and commissioned as planned in late 2027, the Lone Tree autoclave and CIL plant ("Lone Tree" or the "Plant") is expected to serve as the centralized processing hub for the Company's three underground gold projects and a key cornerstone asset as the Company transitions from toll milling to an owner-operator processing model. Based on the Company's December 2025 engineering study, the Plant is expected to significantly reduce current third-party processing costs resulting in increased cash margins by between $1,000 and $1,500 per ounce of gold, depending on grade and gold price. The Plant was previously operated by Newmont Corporation with significant existing infrastructure located immediately adjacent to Interstate 80.

Bulk demolition was completed in the third quarter of 2026 as planned, and mobilization has begun in preparation for the start of initial construction, with a focus on civil preparation and concrete work. Detailed engineering and procurement continue to advance in line with the construction and commissioning schedule with approximately 74% of procurement packages, by value, awarded as of the end of September 2026.

Refurbishment timing and costs incurred to date remain in line with the Company's December 2025 engineering study, which included a total capital cost estimate of $430 million, inclusive of approximately 12% contingency, owner's cost, and capital spares. Cash expenditures to date are trending below the Company's 2026 guidance of between $140 million to $160 million. Overall labor costs to date are running approximately 5% to 10% above initial estimates, reflecting higher wages and incidentals due to the competitive labor market in Northern Nevada, however these are within the allotted project contingency. Total project capital remains largely as expected with approximately 10% of the total project contingency drawn down and approximately 44% of capital committed at the end of the third quarter of 2026. The Company expects all major procurement and contracts to be in place by the end of 2026 providing greater certainty around the projected cost to complete the project.

The Plant is federally permitted. State level permits have been received on schedule as of the end of September to allow for the mobilization of site contractors to begin construction. The Plant is permitted for the existing operational components in use and the receipt of normal course design and environmental state permits remains on track.

Based on 85% plant availability, Lone Tree is expected to process approximately 2,250 tonnes per day, or approximately 825,000 tonnes per annum. Using integrated pressure oxidation ("POX") and CIL circuits, Lone Tree is designed to be capable of processing both refractory (sulfide) and non-refractory (oxide) mineralized material. i-80 Gold is one of two gold companies in Nevada with autoclave processing capacity (the other being owned by Nevada Gold Mines Inc., a joint venture between Barrick Mining Corporation and Newmont Corporation).

Updated Development Plan

The Company has updated its development plan to align the Plant feed supply, processing capacity, and capital allocation. Within the updated pipeline of projects, the Company's operating and near-term development projects remain on the initial schedule to create a hub-and-spoke mining and processing platform around Lone Tree, while the sequence of medium-to-long term projects has been updated as follows:

1) Establish hub-and-spoke mining and processing platform: Ramp up Granite Creek underground, bring Archimedes underground into production, and refurbish and commission the Lone Tree Plant as a centralized processing facility.

2) Prioritize Mineral Point open pit as the next major development project: Adds a large-scale open pit heap leach project.

Choreo Appoints Gabriel Rodriguez As Chief Technology Officer

Former LPL Financial technology executive to lead advisor technology, platform integration and AI development

Rodriguez will report to CEO Jason Van de Loo and join Choreo's Charlotte-based executive leadership team

CHICAGO, Oct. 14, 2026 /PRNewswire/ -- Choreo, LLC ("Choreo" or "the firm") announced today that Gabriel Rodriguez has been named Chief Technology Officer. He will report to Chief Executive Officer Jason Van de Loo, join the firm's executive leadership team and be based in the Charlotte, North Carolina office.

Rodriguez will build the technology foundation for Choreo's next phase of growth, creating a connected platform that helps advisor teams deliver coordinated tax and wealth advice consistently as the firm scales. He will leverage AI to expand advisor capacity and will strengthen the planning, reporting and client engagement tools advisors use every day, supported by training that helps teams adopt them.

"Gabriel has spent his career translating the needs of wealth management professionals into technology that helps them do their jobs more effectively," Van de Loo said. "He brings the technical depth to lead our strategy and the discipline to deliver on it. He understands the role technology plays in supporting advisors and delivering better client experience. That combination will be critical as we expand our capacity to deliver coordinated advice at the intersection of tax and wealth."

Rodriguez brings over 20 years of industry experience. Most recently, he served as Senior Vice President of Technology at LPL Financial, responsible for ClientWorks, the firm's advisor workstation. Before that, he spent six years at Vanguard leading technology architecture and engineering for its U.S. intermediary business. Earlier, he led investment research systems at Wellington Management and developed investment systems at Bain Capital.

His experience spans trading, investment operations, advisor platforms and client service. He has also led AI initiatives focused on advisor productivity and technology integration for acquired firms.

Rodriguez added, "Our industry faces several inflection points simultaneously as the wave of the great wealth transfer is about to crash while some industry observers expect more than a third of financial advisors may leave the industry within the decade. However, a clear solution has emerged in artificial intelligence. But that answer isn't without additional questions, ones that must be considered carefully, strategically and in partnership with operational leadership and advisors in every firm. I'm thrilled to join a firm that understands the importance of this approach and respects the role of technology as a partner for continued growth."

About Choreo, LLC

Choreo is an independent wealth management firm specializing in tax-smart planning for individuals, families, and businesses. With roots in the CPA profession, the firm brings together tax and wealth perspectives to help clients address interconnected financial needs. Choreo operates in more than 40 locations nationwide and provides investment advisory, financial planning and other wealth management services. Choreo, LLC is an SEC-registered investment adviser; registration does not indicate a particular level of skill or training.

Media inquiries

Donald C. Cutler

Haven Tower Group

424.317.4850

[email protected]

SOURCE Choreo, LLC

Share this article

HONOR Introduces HONOR X9e Pro, Breaking the Limits of Its Category

With an industry-largest 11,000mAh battery, 3-metre drop resistance, IP69K protection, a 10,000-nit display and powerful AI features

DUBAI, UAE, Oct. 14, 2026 /PRNewswire/ -- Global AI device ecosystem company HONOR today announced the upcoming launch of HONOR X9e Pro, the first Pro model in the HONOR X Series, building on the series' reputation for exceptional durability while raising the bar across battery, display and AI features and imaging. Designed for users who expect more from their smartphone, HONOR X9e Pro brings together Pro-level capabilities and uncompromising durability to deliver an experience that breaks the limits of its category.

At the heart of the HONOR X9e Pro is a new generation of all-around protection, featuring industry's strongest 3m drop resistance, industry's strongest IP69K water resistance and industry's strongest 85°C high-temperature resistance. The smartphone also introduces a Pro battery powered by the industry's largest 11,000mAh battery, a Pro display featuring the industry's strongest 10,000-nit high-brightness display, and Pro imaging with industry-leading 108MP AI Ultra-clear imaging.

Pro Quality, Built to Withstand More

Setting a new benchmark for all-around durability, HONOR X9e Pro delivers Industry No. 1 all-around drop and water resistance, engineered to withstand demanding conditions with confidence. Its Industry's Strongest Drop Resistance protects against drops of up to 3 metres, supported by an all-new 360° shock-absorbing architecture that provides dynamic drop protection across different terrains. The device has earned the SGS Premium Performance 5-Star rating for Drop Resistance in Harsh Scenarios, covering complex terrains and low-angle drops.[1]

For water resistance, the smartphone features IP69K protection and can withstand submersion in water up to 10 metres, while also supporting underwater photography. It is equally built for extreme heat, offering Industry's Strongest High-Temperature Resistance and withstanding hot-water splashes of up to 85°C.

Pro Battery with Industry's Largest 11,000mAh Battery

An industry-leading 11,000mAh battery[2] gives HONOR X9e Pro up to 3 days of use across a defined mixed-usage scenario. In HONOR internal testing, HONOR X9e Pro was validated for battery endurance to 50°C, covering high-temperature scenarios such as navigation, short- and long-video playback (TikTok and YouTube), calls, standby, and music playback at 50°C.

When charging is available, 80W HONOR SuperCharge[3] helps replenish the battery quickly. With 27W wired reverse charging, HONOR X9e Pro can also act as a portable power source for compatible phones and accessories.

High-efficiency power management is paired with a 6-year[4] battery durability design, supporting more consistent performance over a longer ownership period.

Pro Display with Industry's Highest Brightness Display

Setting a new benchmark in high-brightness smartphone displays, HONOR X9e Pro features an Industry's Strongest High Brightness Display with up to 10,000 nits of ultra-high brightness, delivering clear and vivid visuals even in challenging lighting conditions. The 6.8-inch[5] 1.5K 120Hz[6] display offers smooth, immersive viewing with true-to-life colors, while a hardware-level 1-nit ultra-dark mode reduces glare when users check the screen in dim surroundings.

Designed with eye comfort in mind, the display incorporates 10 HONOR Oasis Eye Comfort technologies respond to different viewing needs, including AI Defocus Display, Motion Sickness Relief, AI Personalized Display, and Ultra Dark Mode.

Intelligent touch recognition also accepts input from gloved or wet hands, so a change in weather or working conditions is less likely to interrupt the task.

Pro Imaging with the Industry-leading 108MP AI Ultra-Clear Camera

Durability does not come at the expense of photography. A 108MP Ultra-Clear Main Camera[7] records fine detail across daylight scenes, night environments, outdoor action, and portraits. CIPA 6.0-level stabilization, combining OIS and EIS, counteracts shake when users shoot handheld, move across uneven ground, or capture fast-changing moments.

Powered by an exclusive intelligent underwater color correction solution, this feature delivers accurate and vibrant colors, ensuring underwater shots are as vivid and lifelike as what the naked eye sees, bringing every frame to life.

Pro AI Capabilities

HONOR X9e Pro brings intelligent AI-powered convenience to every interaction. With AI FreeGrip, the device delivers seamless operation with either hand, while intelligent left- and right-hand recognition automatically detects the active hand and places the capsule on the appropriate side for a truly effortless experience.

It also enables seamless single-handed call answering, keeping everyday communication simple and intuitive. Powered by Google Gemini, HONOR X9e Pro delivers smarter, more natural AI assistance, while Creative Editor 2.0 unlocks enhanced creative tools to help users easily edit, personalize, and transform their content

Color, Price and Availability

HONOR X9e Pro will be offered in four sophisticated color variants: Deep Purple, Reddish Brown, Dawn Gold, Midnight Black.

About HONOR

HONOR is a global leading AI device ecosystem company. It is committed to revolutionizing human-to-device interactions to bridge the AI ecosystem with all consumers in the agentic AI era and beyond. The company endeavors to open industrial boundaries through open, seamless collaboration to co-create a value-sharing ecosystem with industry partners.

With an innovative product portfolio spanning AI phones, PCs, tablets, wearables and more, HONOR aims to empower every human, enabling everyone to embrace the new intelligent world.

[1] This phone has obtained the Swiss SGS Premium Performance Certification for Drop&Crush Resistance, complying with SGS's reliability technical specifications. As a precision electronic product, there is still a risk of damage if the phone falls. Please be careful to avoid drops or collisions.

[2] Battery rated at 10510mAh with a typical capacity of 11000mAh.

[3] It supports maximum 80W wired charge, 80W HONOR charger and cable are required. Actual charging speed may vary depending on environmental conditions and other factors.

[4] The data comes from the HONOR Lab. The battery will have a battery capacity retention rate of more than 80% after 5 years of use according to HONOR Lab simulation of the user's daily behaviors. The actual data will change with different scenarios, please refer to actual usage.

[5] With a rounded corners design applying on the display, the diagonal length of screen is 6.8 inches, when measured according to the standard rectangle (the actual viewable area is slightly smaller).

[6] The screen supports a maximum refresh rate of 120Hz, and the refresh rate may be varied slightly under different app interfaces and game image quality. Please refer to your actual experience.

[7] The rear main camera is a 108MP camera. Actual image resolution may vary depending on the shooting mode.

SOURCE HONOR

Share this article

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years. Active Companies from around the markets with current developments this week include: Oncolytics Biotech, Inc. (NASDAQ: ONCY), Revolution Medicines, Inc. (NASDAQ: RVMD), Eli Lilly and Company (NYSE: LLY), Genmab A/S (NASDAQ: GMAB), Exelixis, Inc. (NASDAQ: EXEL).

The past several weeks have shown how quickly that pipeline is turning into new standards of care. On August 26, the U.S. Food and Drug Administration approved the first broad RAS-targeted medicine for metastatic pancreatic cancer, one of the hardest-to-treat solid tumors. In the first two weeks of October, regulators approved a new first-line use for a blood cancer therapy, a first-line maintenance treatment for HER2-positive metastatic breast cancer and a checkpoint inhibitor combination for stage III mismatch repair-deficient colon cancer, while two large Phase 3 trials in lymphoma and multiple myeloma reported positive topline results.

Gastrointestinal cancers are drawing a growing share of that attention. RAS mutations drive many pancreatic and colorectal tumors, and for years they were considered nearly impossible to drug. Colorectal cancer adds a second challenge: most metastatic cases are microsatellite stable, a form that has generally responded poorly to the checkpoint inhibitors that transformed treatment in other cancers. Companies are attacking the problem from several directions, with targeted RAS inhibitors, new drug combinations and therapies designed to make tumors more visible to the immune system.

Investors will get a fresh look at much of this work soon. The European Society for Medical Oncology holds its 2026 Congress in Madrid from October 23 to 27, one of the largest annual meetings for new cancer data, and two of the companies below have pointed to colorectal cancer updates before year-end.

Oncolytics Biotech, Inc. (NASDAQ: ONCY)

Oncolytics is developing pelareorep, an intravenously delivered immunotherapy designed to turn immunologically "cold" tumors "hot," and colorectal cancer is now at the center of its clinical plans. On September 28 the company reported accelerating enrollment in REO 033, a randomized study in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer that compares pelareorep plus FOLFIRI and bevacizumab with FOLFIRI and bevacizumab alone. Part A is expected to randomize about 60 patients, with objective response rate as the primary endpoint and progression-free survival, overall survival, safety and biomarkers as additional endpoints.

The study builds on REO 022, a smaller non-randomized trial in which the same pelareorep combination produced a 33% objective response rate, median progression-free survival of 16.6 months and median overall survival of 27.0 months. Oncolytics has said it aligned with the FDA on the concept of a potential pivotal Part B expansion, with a proposed accelerated approval path based on response rate and progression-free survival as the basis for potential full approval. Pelareorep holds FDA Fast Track designation in colorectal, anal and pancreatic cancer and has been administered to more than 1,200 patients.

"Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end," said John McAdory, Chief Operating Officer.

The company has also been adding scientific support around the program. In September it reported preclinical results combining pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, in which the combination showed no evidence of antagonism, and it announced a peer-reviewed publication in the Proceedings of the National Academy of Sciences showing that pelareorep changed the liver tumor microenvironment from immunologically inactive to active in preclinical models.

CONTINUED... Read more oncology sector coverage at: Equity Insider

In other industry developments and happenings in the market this week include:

Revolution Medicines, Inc. (NASDAQ: RVMD)

Revolution Medicines announced on August 26 that the FDA approved RASONQUE (daraxonrasib), a once-daily oral tablet, for adults with metastatic pancreatic cancer who have received at least one prior systemic therapy or cannot receive multiagent therapy. In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The company has said it expects to share updated colorectal cancer data and strategy in the fourth quarter of 2026.

"The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer and Chairman.

Eli Lilly and Company (NYSE: LLY)

Lilly announced on October 2 that the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. In the BRUIN CLL-313 trial, Jaypirca reduced the risk of progression or death by 80% compared with bendamustine plus rituximab, with an overall response rate of 94% versus 81%.

Genmab A/S (NASDAQ: GMAB)

Genmab and AbbVie announced on October 5 that the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP met its primary endpoint in newly diagnosed diffuse large B-cell lymphoma, reducing the risk of progression or death by 51% compared with R-CHOP alone. The companies plan to present the data at a future medical meeting and to engage with global regulators.

Exelixis, Inc. (NASDAQ: EXEL)

Exelixis disclosed that the FDA extended its review of zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months after the company submitted updated safety and efficacy information, which the agency classed as a major amendment. The new target action date is March 3, 2027.

Know Which Biotech Names Are Moving First

Clinical readouts and FDA decisions can reprice a stock in minutes. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.

Contact Information:

Media Contact: [email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. It is neither an offer nor a recommendation to buy or sell any security.

This article is being distributed by Equity Insider, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution. MEL was previously paid a fee by Oncolytics Biotech, Inc. for advertising and digital media services under an arrangement that has since expired.

MEL and/or its owners, operators, directors, and affiliates own shares of Oncolytics Biotech, Inc. purchased in the open market, and reserve the right to buy and sell shares of Oncolytics Biotech, Inc. at any time without any further notice. The prior compensation and this share ownership constitute a conflict of interest as to our ability to remain objective in our communication regarding Oncolytics Biotech, Inc. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision. There may also be third parties who hold shares of Oncolytics Biotech, Inc. and may liquidate their shares, which could have a negative effect on the price of the stock.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Clinical results described in this article are as reported by each company; results from different studies are not directly comparable, and early-stage, preclinical and non-randomized data may not be confirmed in later trials. Be extremely careful: investing in securities carries a high degree of risk, and you may lose some or all of your investment. This document is governed by the laws of Ireland.

Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision.

Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases.

Dr. Daniel Amen calls for greater attention to lifelong brain health following research involving more than 187,000 adults.

NEWPORT BEACH, Calif., Oct. 14, 2026 /PRNewswire/ -- A new JAMA Psychiatry study of 187,341 adults aged 50 and older found that 6.7% of participants diagnosed with ADHD developed mild cognitive impairment or dementia, compared with 3.4% without ADHD. After statistical adjustment, an ADHD diagnosis was associated with a 4.6-fold higher hazard of cognitive impairment.

For psychiatrist and brain imaging expert Daniel G. Amen, MD, founder of Amen Clinics, the findings reinforce a message he has championed for decades: Mental health is brain health.

"For too long, ADHD has been treated primarily as a problem with attention, behavior, or motivation," said Dr. Amen. "But ADHD is a brain-based condition. When we ignore the brain and the other risk factors that threaten it, we may miss opportunities to protect people's memory, mood, and long-term health."

Brain Imaging and Early Awareness

Dr. Amen's clinical approach includes brain SPECT imaging, which measures patterns of cerebral blood flow and activity. He believes evaluating brain function alongside symptoms, health history and risk factors can support a more individualized approach to care. The new study did not examine SPECT, and SPECT is not an established screening test for predicting dementia decades before symptoms appear.

"One of the most important lessons from our brain imaging work is that people with similar symptoms can have very different patterns of brain function," Amen said. "If you want to understand a person's behavior, you must also consider the health and function of the organ that produces it."

The 11 BRIGHT MINDS Risk Factors

Dr. Amen's BRIGHT MINDS framework highlights 11 areas relevant to brain health: Blood flow, Retirement and aging, Inflammation, Genetics, Head trauma, Toxins, Mental health, Immunity and infections, Neurohormones, Diabesity, and Sleep. ADHD may make certain health routines and coexisting conditions more difficult to manage, which makes individualized assessment especially important.

"ADHD does not automatically cause all 11 BRIGHT MINDS risk factors," Amen explained. "But it can make some of them more likely or harder to manage. And when risk factors accumulate, protecting the brain becomes even more important."

ADHD Is Not a Dementia Diagnosis

The observational study does not establish that ADHD causes Alzheimer's disease or dementia, and it does not determine whether ADHD treatment prevents cognitive decline. Dr. Amen encourages adults to discuss new or progressive memory symptoms with a qualified clinician and address modifiable health risks, including physical inactivity, high blood pressure, metabolic conditions, insufficient sleep, harmful substance use and untreated mental health concerns.

"Having ADHD does not mean dementia is inevitable," Amen said. "It means we should be more intentional about protecting the brain. The earlier we identify and address the risks, the more opportunities we have to support a healthier future."

His Amen WHOLE-4 approach also emphasizes Brain and Body, Mind, Relationships and Spirit. With National Alzheimer's Disease Awareness Month approaching in November, Dr. Amen hopes the research sparks earlier conversations about lifelong cognitive health.

About Dr. Daniel G. Amen

Daniel G. Amen, MD, is a double board-certified psychiatrist, founder and CEO of Amen Clinics, and an author and educator on brain health. For more than 40 years, he has advocated for integrating brain biology, mental health, lifestyle and brain imaging into psychiatric care.

More information: AmenClinics.com | Dr. Amen on Instagram

Media Contact

Jordyn Dean | Publicist, Amen Clinics | [email protected]

Research: Bauer-Negrini G, et al., JAMA Psychiatry (October 7, 2026)

SOURCE Amen Clinics, Inc.

Share this article

Best Sharps Disposal for Infusion Services (2026): Sharps Assure Recognized for Convenient Mail-Back Solutions by Consumer365

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Consumer365 has recognized Sharps Assure as a notable option for organizations researching the best sharps disposal for infusion services in 2026. The recognition focuses on its convenient mail-back retrieval systems, multiple container capacities, prepaid return materials, tracking documentation, and structured approach to sharps disposal across a range of infusion environments.

Best Sharps Disposal for Infusion Services

- Sharps Assure - a provider of mail-back sharps disposal solutions with multiple container capacities, prepaid return shipping, tracking documentation, and disposal records.

Infusion services extend across many areas of healthcare. Treatment settings may provide IV hydration, antibiotics, iron, immune therapies, specialty medications, blood products, and other intravenous treatments. Many of these procedures generate needles, syringes, and other contaminated sharps that require appropriate collection and disposal.

Sharps Assure provides mail-back systems intended to help healthcare organizations manage that waste from point-of-use collection through retrieval. The range supports facilities with different treatment volumes, available space, and disposal needs, including smaller practices and organizations operating across multiple locations.

Mail-Back Disposal Supports a Range of Infusion Services

The sharps disposal requirements of an infusion practice depend partly on the types and volume of treatments provided.

A specialty clinic offering occasional infusions may generate sharps at a relatively modest rate. A dedicated outpatient infusion center operating several treatment stations throughout the day may fill containers more quickly. Healthcare organizations with multiple clinics may face another challenge, since waste volume can vary significantly by location.

Despite those differences, needles and other contaminated sharps need to be discarded into appropriate containers after use.

OSHA requirements state that contaminated sharps containers must be closable, puncture resistant, leakproof on the sides and bottom, and properly labeled or color coded. Containers must also remain easily accessible, upright during use, and replaced routinely before overfilling.

Sharps Assure addresses the next stage through a mail-back retrieval model. Instead of treating the collection container and disposal logistics as completely separate processes, its systems incorporate materials intended to support both collection and return.

The approach applies broadly across infusion services and is not tied to one particular medication category or treatment type.

Multiple Capacities Accommodate Different Treatment Volumes

Sharps generation can vary substantially from one infusion setting to another.

Sharps Assure offers several container capacities, including compact formats and 1-gallon, 2-gallon, 3-gallon, and 5-gallon configurations. This range allows healthcare organizations to consider actual usage when selecting a system.

Smaller containers may be appropriate for individual treatment rooms, lower-volume practices, or locations with limited available space. Larger systems may be better suited to facilities where sharps are generated consistently throughout the day.

Container design also varies across the range. Available products include vertical-entry configurations as well as larger options that accommodate horizontal or vertical entry. Those differences allow organizations to consider how the container will fit within existing treatment and disposal workflows.

Several practical factors can influence selection:

- Treatment volume: Higher patient throughput may require greater capacity or more frequent container replacement.

- Available space: Physical dimensions can matter in smaller treatment rooms and distributed clinics.

- Placement: Containers should remain readily accessible where sharps are generated.

- Entry design: Different container openings may suit different treatment environments.

- Waste category: Specialized waste streams should be evaluated separately and placed in products intended for that purpose.

These considerations help healthcare organizations choose a sharps disposal setup that fits different treatment volumes, available space, and day-to-day workflows.

A Structured Retrieval Process Extends Beyond the Container

Consumer365's recognition also considers what happens after a sharps container is ready for removal.

Depending on the Sharps Assure configuration, retrieval systems can include protective packaging, an outer shipping carton, sealing materials, instructions, prepaid return shipping, and shipping documentation.

Bringing these materials together can help practices establish the return procedure in advance rather than determining how to transport a full container only after it reaches capacity.

Tracking documentation provides another part of the process. Shipping records can help healthcare organizations follow the retrieval, while disposal documentation can support internal recordkeeping once the waste has been processed.

The structure can be relevant for smaller medical practices that generate sharps steadily but may not require the same waste collection schedule as larger healthcare facilities.

It can also support distributed organizations. A network with several treatment locations may have different sharps volumes at each site. Mail-back retrieval allows each location to select an appropriate container and follow the established return process according to its own usage.

USPS requirements apply to qualifying sharps waste sent through the mail. State and local rules may also affect medical-waste handling. Healthcare organizations should follow the retrieval system instructions and confirm requirements applicable to the facility and waste involved.

Sharps Assure Recognized for Flexible Mail-Back Sharps Management

Consumer365's recognition of Sharps Assure centers on its broader approach to sharps retrieval across healthcare environments with varying disposal needs.

The system is relevant to infusion services because infusion care spans many treatment categories. Hydration, antibiotic therapy, iron infusions, immune treatments, specialty medications, and other intravenous services can all involve the use of needles and related sharps.

Multiple container capacities allow organizations to choose a format aligned with waste generation. Mail-back materials provide an established return process. Tracking and disposal documentation support administrative recordkeeping after sharps leave the treatment location.

Specialized products are available when a particular waste category requires a separate approach, but general infusion sharps disposal remains the broader application.

For infusion providers evaluating disposal options in 2026, the appropriate system depends on treatment volume, available space, container placement, waste classification, facility procedures, and applicable regulations.

Sharps Assure provides a mail-back model designed around those practical considerations. The combination of different container capacities and a structured retrieval process gives infusion practices a way to match sharps disposal more closely with the way each treatment location operates.

To read the full article, visit the Consumer365 website.

About Sharps Assure: Sharps Assure offers innovative solutions for safe and compliant disposal of medical sharps and pharmaceutical waste. Their services cater to small-scale needs, providing a mail-back disposal program that includes prepaid postage for convenient and cost-effective disposal.

About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided.

SOURCE Consumer365.org

Share this article

Jeddah Hotel Rooftop Pool Built to Last with Penetron System

The Hilton Garden Inn in Jeddah, Saudi Arabia, was officially unveiled in late 2026, adding another notable luxury hospitality destination to the popular Red Sea resort. The Penetron System of crystalline concrete waterproofing products was specified to provide a durable waterproofing solution for the hotel's key concrete structures.

ORLANDO, Fla., Oct. 14, 2026 /PRNewswire/ -- "A rooftop swimming pool on a luxury hotel presents potentially serious design and performance risks, with hydrostatic loading on an elevated structural slab and guest rooms below exposed to any leakage," points out Sam Annous, Director and Partner of Penetron Middle East.

While a traditional membrane system can offer installation speed, any membrane breach over the service life of the pool risks staining and damage to ceilings, walls, and guest rooms below.

"The project brief for the Hilton Garden Inn was to protect the below-grade concrete structures and deliver a pool that remains watertight for the life of the building without relying on a surface membrane system," adds Sam Annous.

The Penetron Middle East team specified an integral waterproofing approach using three Penetron systems working together:

- PENETRON ADMIX, dosed at the batching plant, transforms structural concrete into a self-healing, waterproof matrix that resists chloride ingress, carbonation, and chemical attack.

- PENEBAR SW45 swellable waterstop strips, combined with PENEBAR PRIMER, seal every construction joint and penetration, which are typically the weakest points in any water-retaining and below-grade structure.

- PENETRON slurry and PENECRETE MORTAR are used to address localized cracks and tie holes and to finish any visible defects.

Once exposed to moisture, PENETRON ADMIX reacts with calcium hydroxide and water to form insoluble crystalline structures within the concrete, sealing capillaries and static cracks up to 0.5 mm and reactivating when new moisture appears. The resulting resistance to hydrostatic pressure means the matrix itself becomes waterproof, with no surface layer to puncture, peel, or age out.

After commissioning, the pool was filled and held for testing. The walls of the floor below were found to be almost entirely dry, with no water leakage detected beneath the slab. PENETRON ADMIX performed as a standalone waterproofing system, with no membrane required.

"The Hilton Garden Inn in Jeddah is the latest Hilton Hotel project to specify the Penetron System," adds Sam Annous. "Our integral crystalline waterproofing solution continues to enjoy growing success across the region."

The Penetron Group is a leading manufacturer of specialty construction products for concrete waterproofing, concrete repairs, and floor preparation systems. The Group operates through a global network, offering support to the design and construction community through its regional offices, representatives, and distribution channels.

For more information on Penetron waterproofing solutions, please visit penetron(dot)com or Facebook(dot)com/ThePenetronGroup.

SOURCE The Penetron Group

Share this article